SAN DIEGO, Oct. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company’s novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.
(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)
Both studies were completed in collaboration with Dr. Filip Janku in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston. Trovagene is developing proprietary cell-free DNA urinary assays for molecular testing as a non-invasive alternative to mutation testing of tumor tissue.
The abstracts accepted for presentation during the “Molecular Classification of Tumors” poster session at the AACR-NCI-EORTC conference are:
Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by digital droplet PCR (Abstract #B175)
- Monday, October 21, 12:30 3:00 p.m. and 6:30 7:30 p.m.
- Location: Exhibit Hall C-D
Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing (Abstract #B177)
- Monday, October 21, 12:30 3:00 p.m. and 6:30 7:30 p.m.
- Location: Exhibit Hall C-D
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.
Contact:
Amy Caterina
Trovagene, Inc.
Investor Relations
858-952-7593
acaterina@trovagene.com
[1] American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer
SOURCE Trovagene, Inc.
Help employers find you! Check out all the jobs and post your resume.
